| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | C-C chemokine receptor type 1;C-C CKR-1;CC-CKR-1;CCR-1;CCR1;Macrophage inflammatory protein 1-alpha receptor;MIP-1alpha-R;RANTES-R;CD191;Ccr1;Cmkbr1; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | E.coli-derived human PAR-3/PARD3 recombinant protein (Position: M1-Q1346). |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Target | |
| UniProt # |
Overview
Anti-PAR-3/PARD3 Antibody Picoband® is an antibody for PARD3 detection raised in Rabbit (Polyclonal, Rabbit IgG), with reported reactivity: Human. Commonly used in WB, IHC, IF, ICC, Flow Cytometry, ELISA workflows.
Key elements and design rationale
- Target: PARD3 (C-C chemokine receptor type 1); UniProt: Q8TEW0
- Antibody format: Rabbit, Polyclonal, Rabbit IgG
- Molecular weight: 151 kDa, calculated 40895 MW
- Applications: WB, IHC, IF, ICC, Flow Cytometry, ELISA
Vendor description (summary): Boster Bio Anti-PAR-3/PARD3 Antibody Picoband® catalog # A01897-2.
Biological background
Biological context: Receptor for a C-C type chemokine. Binds to MIP-1-alpha, RANTES, and less efficiently, to MIP-1-beta or MCP-1 and subsequently transduces a signal by increasing the intracellular calcium ions level. Responsible for affecting stem cell proliferation.
Expression and localization notes: cellular localization: Cell membrane; Multi-pass membrane protein., tissue context: Detected in the heart, spleen, lung, peritoneal exudate cells and leukocytes..
Common research applications
- Western blotting (WB): Compare PARD3 levels across samples and conditions using appropriate loading and biological controls.
- Immunohistochemistry (IHC): Evaluate spatial distribution of PARD3 in tissue sections, considering fixation and antigen retrieval effects.
- Immunofluorescence / ICC: Assess subcellular localization patterns and co-localization with compartment markers in cultured cells.
- Flow cytometry: Quantify PARD3-positive populations in single-cell suspensions with appropriate gating and controls.
- ELISA: Use antibody-based detection formats to assess antigen presence or binding in plate-based assays.
Notes for experimental interpretation
- Account for isoforms, post-translational modifications, and sample-specific processing that can shift apparent molecular weight or epitope accessibility.
- Use positive/negative biological controls where possible (e.g., known-expressing cells/tissues, knockdown/knockout models) and include appropriate secondary-only/isotype controls for imaging workflows.
Additional product notes (from provided fields)
- Background: Partitioning defective 3 homolog is a protein that in humans is encoded by the PARD3 gene. This gene encodes a member of the PARD protein family. PARD family members interact with other PARD family members and other proteins; they affect asymmetrical cell division and polarized cell growth. Multiple alternatively spliced transcript variants have been described for this gene.
- Cross reactivity: No cross-reactivity with other proteins.
- Cellular localization: Cell membrane; Multi-pass membrane protein.
- Tissue details: Detected in the heart, spleen, lung, peritoneal exudate cells and leukocytes.
- Research category: Chemokines,Immunology,Innate Immunity
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
